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Innovations
Accelerator Mass Spectrometry for Measuring
Low-Dose Carcinogen Binding to DNA
For many environmental chemicals, scien-
tists must extrapolate data from high-dose
animal experiments to estimate human risk
from low exposures. Because there is often
great disparity between doses, intermediate
markers of exposure that respond to lower
doses must be used. One common marker
is the DNAadduct: DNA covalently bound
to an active chemical intermediate.
Accelerator mass spectometry (AMS) is a
new method that significantly increases the
accuracy and range of measuring DNA
adducts.
DNA binding has traditionally been
measured by tagging the chemical ofinter-
est with carbon-14 or hydrogen-3 isotopes
and, after extensive procedures to eliminate
any unbound isotope, counting the isotope
label still covalently bound to the DNA.
More recently, monoclonal antibodies have
been developed to recognize an intermedi-
ate of the chemical covalently bound to a
DNA base and have been used in
immunoassays to quantify adduct binding.
Another sensitive method to analyze DNA
adducts is breaking down DNA into its
constituent nucleotides by enzymatic diges-
tion, followed by labeling the nucleotides
with phosphorous-32 and separating
adducted from normal nucleotides by mul-
tidimensional thin-layer chromatography.
Both monoclonal antibodies and enzymat-
ic digestion are useful for assessing DNA
damage, but they lack either sensitivity at
low doses or the capability to give reliable
quantitative information. Both methods
do, however, have the advantage of allow-
ing assessment ofhuman exposures because
they are noninvasive (people do not have
to be exposed to radioactivity or analytical
chemicals). In contrast, AMS allows for an
ultrasensitive measurement of radiolabeled
compounds and thus is ideally suited for
measuring carcinogen-DNA adducts fol-
lowing an extremely low-dose exposure.
AMS allows the investigator to analyze
small samples, measure with extreme preci-
sion, and detect extremely small amounts
oflabeled compound.
HowAMSWorks
Accelerator mass spectrometry uses a tan-
dem electrostatic (Van de Graaff) accelera-
tor to dissociate and accelerate negative
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ions generated from graphite by a cesium-
sputter ion source. The ions are sorted by
a low-energy mass spectrometer, which
selects the proper mass and injects the ions
into the accelerator beam tube. The
increasing positive potential in the beam
tube accelerates the negative ions toward
the 2-15 megavolt terminal at the center
ofthe accelerator. Quadrapole lenses select
and focus the correct ion and charge state
for a second high-energy mass spectrome-
ter, which separates the rare isotope from
the ion beam of an abundant elemental
isotope. A third magnetselects by momen-
tum. The ion ofinterest is further selected
based on its velocity, and finally the ions
of interest are counted in a multianode
gas-ionization detector. All these steps are
necessary to obtain 1 part in 1015 sensitivi-
ty in detecting rare isotopes such as 14C.
For counting samples with 14C,
approximately 1 milligram of carbon is
optimal. This material is generated by
combusting the sample to carbon dioxide
and reducing it to graphite on acobalt cat-
alyst This is the rate-limiting part of the
AMS measurement: one technician can
batch process approximately 250 samples
per week. Although AMS is a super-sensi-
tive scintillation counter, it does have the
short-comings ofisotope counting, includ-
ing contamination problems.
Measuring Carcinogens and DNA
Traditional animal bioassays use either the
maximum tolerated dose (MTD) or doses
close to this level. Yet most environmental
exposures are orders of magnitude lower.
Therefore, methods like DNA binding,
cytogenetics, and mutation analysis are
used to assess intermediate genetic and
molecular damage leading to carcinogene-
sis. These methods allow exposures to be
measured at lower levels than the tradi-
tional cancer bioassays, but in most cases
do not approach actual levels in food, the
workplace, or the environment. Measure-
ment of DNA adducts is probably the
most sensitive intermediate method of
assessing events leading to cancer.
Immunoassay analysis can detect 1 adduct
per 108 nucleotides, and 32P-postlabeling
can detect 1 adduct per 1010 nucleotides.
In practice, quantitative measurements are
one to two orders ofmagnitude less sensi-
tive than these limits. In contrast, AMS
can directly measure 14C nuclei in as few
as 1000 atoms, two orders of magnitude
below the natural abundance of14C in liv-
ing organisms. Therefore, AMS can accu-
rately measure 1 adduct per 1011 bases, or
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1 adduct per 100 mammalian cells.
Kenneth W. Turteltaub and colleagues
at the Lawrence Livermore National
Laboratory made the first measurements of
DNA adducts using AMS. They discov-
ered a linear relationship of binding with
dose of the carcinogen 2-amino-3,8-
dimethylimidazo [4,5-f]quinoxaline
(MeIQx) from 1 adduct per 5 x 106
nucleotides to 1 per 1011 nucleotides. 32P-
postlabeling data for MeIQx also fit on the
same linear dose-response curve but in the
higher dose region.
These linear AMS adduct measure-
ments suggest that repair of MeIQx
adducts is not concentration dependent at
even 1 adduct per 100 cells; in fact, it
appears that repair is no more efficient at
these low doses than it is at 1 million times
the damage. The same can be said for
metabolism and any other physiological
activity affecting the steady-state level of
these adducts. Thus, at least for acute
exposures, extrapolation of damage is lin-
ear over an extremely large range ofdoses.
Ifthis relationship holds for other genotox-
ic carcinogens, risk analysis for these types
of compounds can be done with fair cer-
tainty that a linear relationship exists with
respect to dose.
Scientists at Lawrence Livermore have
developed methods that allow separation
of the nucleotide DNA adducts by high-
performance liquid chromatography and
then counting of fractions by AMS. This
procedure allows measurement of specific
adduct levels at extremely low exposures.
The retention times for each individual
adduct, which are derived from high-dose
experiments, are related to peaks seen from
AMS counted fractions.
One drawback ofAMS is that analysis
ofhuman samples such as blood, urine, or
tissue would require the administration of
both carcinogens and labeled material
before analysis. Although less than 0.1 mil-
lirad of radiation and 100-500 nano-
gram/kilogram dose of chemical would be
an insignificant exposure for a human, it is
difficult to get approval for such studies.
An attractive alternative for analyzing low-
level human exposures is an AMS-modi-
fied radioimmunoassay. This method
would allow detection of specific adducts
by antibodies and then the use ofcompeti-
tion radioimmunoassay coupled to AMS to
quantify adducts.
Improvements inAMS
There are three types ofpotential improve-
ments in AMS. First, AMS technology has
more sensitivity than the biological system
allows. This problem can be overcome by
using organisms depleted in 14C. Deple-
tion can be accomplished by growing
organisms on carbon sources derived from
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HowAMS works. Diagram illustrates the components of an accelerator mass spectrometer and the flow
of particles through the equipment.
petroleum (all the 14C has decayed in feed-
stocks derived from these materials).
Turteltaub showed that it is possible to
gain two orders ofsensitivity by using bac-
teria such as Methylosinus trichosporium,
which are grown on petroleum-derived
methane as their sole carbon source. The
same methodology can be used in rodent
diets. Well-balanced diets containing pro-
tein and carbohydrate sources depleted in
14C could easily gain one order ofsensitivi-
ty for DNA binding, allowing detection of
more than 1 adduct per 101 nucleotides.
Unlabeled nutrients and biochemicals
would act as iftheywere labeled in rodents
fed such a diet (carbon dating of those
with 20% residual 14C would make them
equivalent to a 13,000-year-old organism)
because oftheir natural 4C levels. Labeled
experiments could be done without isotope
tracers in these rodents.
Second, further improvements should
allow for detection using a second isotope.
This would give all the advantages ofdou-
ble-isotope counting such as rates of for-
mation and loss of nutrients, adducts, or
biologically important macromolecules. At
Lawrence Livermore, 3H has been counted
with the same device as 14C using a differ-
ent detector. This isotope is as sensitive as
14C (approximately 1 part per 10i5), but
sample preparation methodology needs to
be developed father. Currently, a method
is being tested to measure Tritum (TiH2)
for the ion source in the form ofTiH2. In
addition to allowing double-label experi-
ments, tritium capability would allow a
much cheaper source of labeled com-
pounds. Although tritium introduces
problems associated with isotope
exchange, it should be valuable to the bio-
medical AMS capability.
Third, the instrument currently being
used at Lawrence Livermore is designed for
research on isotopes up to mass 131 (i.e.,
1311). Although this instrument is opera-
tional in an automatic mode, where 60
samples can be run in batch mode in less
than 2 hours (multiple batches per day), the
capital cost and maintenance of a research
AMS facility is expensive and is not needed
for biomedical samples. An accelerator for
14C and 3H measurements that would cost
under $1 million and fit in a typical
research laboratory space is a goal ofAMS
development. Such equipment would allow
more ofthe biomedical research communi-
ty to conduct these types ofhigh-sensitivity
measurements.
Future Directions
The capability to make high-sensitivity
measurements has applications throughout
biomedicine. Receptor studies where
receptor and ligand interactions are limit-
ed would benefit from application of
AMS. Questions about interactions of
chemicals with DNA at any dose could be
examined. AMS could also be used to
determine ifchemicals bind DNA, even at
the lowest levels detectable following high
exposures.
Another important arena for AMS is
the radioimmunoassay field. Turteltaub
and colleague John Vogel have shown that
a very sensitive, direct radioimmunoassay
can be adapted for use with AMS with a
sensitivity ofless than 100 attomoles (10-18
moles) for the pesticide heptachlor. They
also have measured the AIDS drugAZT in
a competitive radioimmunoassay at the
low femtomole level (105 moles). The
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advantage ofthis type ofassay for humans
is that adducts and drugs can be measured
without having to dose with radiolabeled
chemicals.
AMS is valuable in experiments where
high sensitivity, low sample size, or low
molecular interactions are problems. DNA
adducts appear linear, at least in acute dos-
ing experiments over a million-fold range
ofdose. The ability to count such low lev-
els of material with precision and speed
enables scientists to answer a large spec-
trum ofquestions.
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